Diabetes research and clinical practice最新文献

{"title":"Continuous glucose monitoring with low-glucose alerts in insulin-treated drivers with diabetes: A randomized crossover study","authors":"Ryutaro Maeda ,&nbsp;Takeshi Onoue ,&nbsp;Keigo Mizutani ,&nbsp;Koji Suzuki ,&nbsp;Tomoko Handa ,&nbsp;Tomoko Kobayashi ,&nbsp;Shintaro Iwama ,&nbsp;Takashi Miyata ,&nbsp;Mariko Sugiyama ,&nbsp;Daisuke Hagiwara ,&nbsp;Hidetaka Suga ,&nbsp;Fumie Kinoshita ,&nbsp;Hiroshi Arima","doi":"10.1016/j.diabres.2025.112074","DOIUrl":"10.1016/j.diabres.2025.112074","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to evaluate the effectiveness of continuous glucose monitoring (CGM) with low-glucose alerts for preventing hypoglycemia in insulin-treated drivers with diabetes.</div></div><div><h3>Methods</h3><div>This single-center, open-label, randomized crossover study involved 30 insulin-treated participants with diabetes who drove cars at least thrice weekly in Japan. Participants underwent two 4-week periods: an alert period using CGM with active low-glucose alerts and a no-alert period using blinded CGM without low-glucose alerts, separated by an eight-week washout period. The primary outcome was the percentage of time below range (TBR; &lt;3.9 mmol/L).</div></div><div><h3>Results</h3><div>Twenty-seven of the 30 participants completed the CGM analysis. Although the TBR did not differ between the alert and no-alert periods among all participants, it significantly decreased during the alert period compared with the no-alert period among the participants with type 1 diabetes (−4.4 [95 % confidence interval − 8.7, −0.08]%, p = 0.047). The incidence of low-glucose when driving was significantly lower during the alert period than during the no-alert period (19 % vs. 33 %, p = 0.041).</div></div><div><h3>Conclusion</h3><div>Low-glucose alerts improved the TBR in drivers with type 1 diabetes and reduced the incidence of low-glucose while driving among all insulin-treated drivers, suggesting that these alerts may ensure the safety of insulin-treated drivers.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112074"},"PeriodicalIF":6.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using continuous glucose monitoring to prescribe an exercise time: a randomised controlled trial in adults with type 2 diabetes","authors":"Courtney R. Chang,&nbsp;Lauren A. Roach,&nbsp;Brooke M. Russell,&nbsp;Monique E. Francois","doi":"10.1016/j.diabres.2025.112072","DOIUrl":"10.1016/j.diabres.2025.112072","url":null,"abstract":"<div><h3>Purpose</h3><div>Growing evidence suggests the exercise timing, time-of-day it is performed, is important for maximizing glycemic benefits in type 2 diabetes (T2D). This randomized controlled trial investigated the impact of utilizing continuous glucose monitoring to personalise exercise timing on peak hyperglycaemia and cardiometabolic health in people with T2D.</div></div><div><h3>Methods</h3><div>Adults with T2D (HbA1c: 7.2 ± 0.8 %; Age: 63 ± 12 y; BMI: 29 ± 5 kg/m²) were randomized to eight weeks: i) waitlist control (CTL, eight week CTL then re-randomized to interventions), ii) 22-min daily exercise beginning ∼ 30 min before peak hyperglycemia (ExPeak) or iii) 22-min daily exercise ∼ 90 min after peak hyperglycemia (NonPeak). Time of peak hyperglycemia was pre-determined for each participant using the median of a 14-d habitual continuous glucose monitoring (CGM) period. Glycemic control (HbA1c [primary outcome], CGM), vascular function (flow-mediated dilation [FMD]), arterial stiffness, blood pressure) and body composition were assessed. Linear mixed models compared changes across time between groups.</div></div><div><h3>Results</h3><div>There was no intervention effect for HbA1c, however there was a significant interaction for changes in 24-h peak glucose and %FMD between groups. Compared to CTL, both intervention groups significantly lowered peak glucose (ExPeak: 95 %CI: −2.0 to −0.3 mmol/L, NonPeak: CI: −2.3 to −0.6 mmol/L) and %FMD increased (ExPeak: 95 %CI: 0.6 to 1.5 %, NonPeak: 95 %CI: 0.0 to 1.1 %). Adherence to interventions was high for both intervention groups (&gt;90 %).</div></div><div><h3>Conclusion</h3><div>Prescribing exercise to target peak hyperglycemia did not improve HbA1c; however cardiometabolic health outcomes improved in both groups prescribed an exercise time compared to control. Personalizing exercise prescription by prescribing a time to exercise may be a novel approach to improve health outcomes and physical activity participation.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112072"},"PeriodicalIF":6.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of an individual weight-loss model for patients with diabetes treated with metformin","authors":"Yujia Han ,&nbsp;Jia Zhang ,&nbsp;Weihao Wang ,&nbsp;Kaixin Zhou ,&nbsp;Wenying Yang ,&nbsp;Qi Pan ,&nbsp;Zedong Nie ,&nbsp;Lixin Guo","doi":"10.1016/j.diabres.2025.112073","DOIUrl":"10.1016/j.diabres.2025.112073","url":null,"abstract":"<div><h3>Aims</h3><div>To develop a machine learning model for predicting weight loss response to metformin in Chinese patients with type 2 diabetes.</div></div><div><h3>Methods</h3><div>Data were obtained from three Chinese randomized controlled trials (RCT) screening newly diagnosed diabetes patients who received metformin monotherapy. Multiple machine learning methods, including gradient boosting regressor (GBR), were used to predict weight loss at the end of treatment based on baseline clinical characteristics and weight data collected at baseline and after up to weeks 4, 8, or 12. GBR was identified as the optimal model on the validation set according to minimum Mean Absolute Error (MAE) for subsequent analyses. Model performance on predicting categorical weight loss at 3% or 5% was measured using classification metrics, including the area under the curve (AUC), accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).</div></div><div><h3>Results</h3><div>Three trials with a total of 1325 individuals with diabetes were pooled in the final analysis. We randomly selected 1126 individuals for the training and the validation group and 119 for the test group. In the test set, all AUC values exceeded 0.71 (with a maximum of 0.83). Additionally, the precision improved when weight data from the 4, 8, and 12-week time points were included in the training group. An online web-based tool was constructed based on the machine learning prediction model.</div></div><div><h3>Conclusions</h3><div>The developed machine learning model can be used to predict the individual weight loss responses to metformin and provide new insights for clinical practice regarding weight management in Chinese patients with diabetes.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112073"},"PeriodicalIF":6.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143529710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poor glycemic status as a risk factor for dementia in type 2 diabetes population: Findings from the Taiwan’s National Health Insurance Database","authors":"Chia-Ling Lin ,&nbsp;Wu-Chien Chien ,&nbsp;Chun-Ping Lin ,&nbsp;Chi-Hsiang Chung ,&nbsp;Fei-Ling Wu","doi":"10.1016/j.diabres.2025.112065","DOIUrl":"10.1016/j.diabres.2025.112065","url":null,"abstract":"<div><h3>Aim</h3><div>This study explored the association between poor glycemic status (PGS; hyperglycemia, hypoglycemia, or their combination [mixed]) and dementia risk in patients with type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, we conducted a secondary analysis using data from Taiwan’s National Health Insurance Database spanning the years 2000 to 2015. We employed propensity score matching (1:1) based on sex, age, index year, and inclusion date to select a comparison cohort, the Cox proportional-hazards regression analysis was performed to assess the effect of PGS on the risk of dementia. Kaplan–Meier survival analysis was performed to compare the cumulative incidence of dementia between patients with T2D and PGS and those without PGS.</div></div><div><h3>Results</h3><div>Among 192,977 patients with T2D, 57,893 had PGS during the follow-up period. Of them, 4,342 patients (7.5 %) developed dementia. PGS status was positively associated with dementia risk (adjusted hazard ratio: 2.01; 95 % confidence interval [CI]: 1.58–2.68). The risks of dementia were 1.56 (95 % CI: 1.22–2.08) for hypoglycemia, 1.64 (95 % CI: 1.30–2.18) for hyperglycemia, and 3.10 (95 % CI: 2.48–4.12) for mixed PGS.</div></div><div><h3>Conclusions</h3><div>In patients with T2D, PGS is associated with an increased risk of dementia, particularly in those experiencing significant fluctuations in glycemic levels.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112065"},"PeriodicalIF":6.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143521095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transitioning between automated insulin delivery systems: A focus on personalisation","authors":"Pilar Isabel Beato-Víbora ,&nbsp;Ana Chico ,&nbsp;Jesus Moreno-Fernandez ,&nbsp;Sharona Azriel-Mira ,&nbsp;Lia Nattero-Chávez ,&nbsp;Rosario Vallejo Mora ,&nbsp;Núria Alonso-Carril ,&nbsp;Olga Simó-Servat ,&nbsp;Eva Aguilera-Hurtado ,&nbsp;Luz María Reyes Céspedes ,&nbsp;Marisol Ruiz de Adana ,&nbsp;Marta Domínguez ,&nbsp;Rosa Márquez-Pardo ,&nbsp;Gonzalo Díaz-Soto ,&nbsp;María Asunción Martínez-Brocca ,&nbsp;Khusama Alkadi Fernández ,&nbsp;Macarena Alpañés Buesa ,&nbsp;Martín Cuesta Hernández ,&nbsp;Carmen Quirós","doi":"10.1016/j.diabres.2025.112070","DOIUrl":"10.1016/j.diabres.2025.112070","url":null,"abstract":"<div><h3>Background</h3><div>Automated insulin delivery (AID) systems are the most effective treatment for type 1 diabetes (T1D). When targets are not achieved, transitioning between AID systems is an option. The aim was to assess the impact of switching between systems on glucose control and user satisfaction.</div></div><div><h3>Methods</h3><div>A multicenter, cross-sectional analysis was conducted. T1D subjects who had switched between AID systems were included. Glycaemic control was compared before the switch, after 14 days, and after 3 months of use of the new system. The participants completed a satisfaction survey.</div></div><div><h3>Results</h3><div>96 subjects were included (age: 40.8 ± 11.5 years, 73 % female, HbA1c: 6.94 ± 0.68 % (52.3 ± 7 mmol/mol)). The AID systems evaluated included MiniMed^TM-780G, Diabeloop-DBLG1, Tandem-t:slim-x2^TM-Control-IQ^TM, and CamAPS-FX. GMI improved from 6.92 ± 0.49 % to 6.71 ± 0.37 % after 14 days and to 6.68 ± 0.36 % after 3 months and Time in Range 70–180 mg/dl increased from 70.53 ± 11.43 % to 75.73 ± 8.33 % after 14 days and to 75.65 ± 7.64 % after 3 months (p &lt; 0.001 to baseline). The majority of the participants reported higher satisfaction. The factors that most affected satisfaction were the size of the system, the performance of the sensor, and the specificities of the control algorithm.</div></div><div><h3>Conclusion</h3><div>Transitioning between AID systems can enhance glucose control and user satisfaction without compromising glycaemic stability during the adjustment period.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112070"},"PeriodicalIF":6.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular risk","authors":"Angelo Avogaro ,&nbsp;Raffaella Buzzetti ,&nbsp;Riccardo Candido ,&nbsp;Salvatore De Cosmo ,&nbsp;Lucia Notarianni ,&nbsp;Eleonora Consolo ,&nbsp;Myriam Luciano","doi":"10.1016/j.diabres.2025.112055","DOIUrl":"10.1016/j.diabres.2025.112055","url":null,"abstract":"<div><div>People with diabetes mellitus (DM) are at a higher risk (2–4 times) for cardiovascular (CV) death and atherosclerotic CV disease (ASCVD) than the general population. A multifactorial approach is recommended to reduce CV risk. Since low-density lipoprotein cholesterol (LDL-C) is a major causal and cumulative risk factor for ASCVD, the management of lipids is a fundamental element in global risk reduction. Intensive lipid lowering therapy (LLT), such as the addition of a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i), to achieve LDL-C goals and reduce the risk of first or recurrent CV events in people with DM at very high CV risk (VHCVR) of ASCVD (i.e. acute coronary syndrome, coronary artery disease, peripheral artery disease) is often required. Alirocumab, a monoclonal antibody against PCSK9, as lipid-lowering therapy offers significant CV benefits and a favourable safety profile in people with DM and a VHCVR, with or without previous CV events. This review highlights the role of LDL-C in the complex pathogenesis of atherosclerosis, summarises the guidelines for CV risk reduction related to LDL-C in patients with DM and a VHCVR, and focuses on the role of alirocumab in managing LDL-C and consequent CV risk reduction in these patients.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112055"},"PeriodicalIF":6.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A scoping review exploring research investigating the influence of carbohydrate counting on eating behaviour and/or disordered eating in type 1 diabetes","authors":"K.R. Rigby ,&nbsp;I. Iturbe ,&nbsp;T. Candler ,&nbsp;R. Anderson ,&nbsp;J.P. Hamilton-Shield ,&nbsp;EC Hinton","doi":"10.1016/j.diabres.2025.112068","DOIUrl":"10.1016/j.diabres.2025.112068","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate evidence describing a potential association between carbohydrate counting (CC) in type 1 diabetes and eating behaviours and/or disordered eating behaviour (DEB).</div></div><div><h3>Methods</h3><div>Systematic literature searches were conducted using MEDLINE, Embase, PsycINFO, Web of Science,<!--> <!-->Scopus, and the trial register Cochrane Central Register of Controlled Trials.</div></div><div><h3>Results</h3><div>37 articles were eligible for review, 28 measured CC, 26 provided evidence of an association between CC and eating behaviours or participants’ relationship to food, and four provided evidence of an association between CC and disordered eating. Evidence suggests that patients using CC are less likely to score highly for DEB.</div></div><div><h3>Conclusions</h3><div>Measures of CC practise and adherence currently do not 1) consider the possible impact of the spectrum of CC strategies used within this cohort, which are often modified and personalised over time or, 2) consider that disordered eating in type 1 diabetes patients is often characterised by binge eating, restricted eating or insulin dose manipulation with inappropriate insulin-to-food calculations or the rejection of CC. Further research considering the range of insulin-to-food strategies practised and varying methods of CC education (particularly in early childhood), would be valuable in ascertaining associations between CC adherence and DEB.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112068"},"PeriodicalIF":6.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daytime napping and risk of incident main adverse cardiovascular events and mortality among adults with type 2 diabetes","authors":"Xiu Hong Yang ,&nbsp;Yao Liu ,&nbsp;Xin Xin Jiang ,&nbsp;Zhen Xing Zhang ,&nbsp;Yi Jun Lu ,&nbsp;Chen Sheng Fu ,&nbsp;Hui Min Jin ,&nbsp;Zhi Bin Ye","doi":"10.1016/j.diabres.2025.112067","DOIUrl":"10.1016/j.diabres.2025.112067","url":null,"abstract":"<div><h3>Aims</h3><div>To explore the link between daytime napping and the risk of major adverse cardiovascular events (MACE) and mortality in individuals with type 2 diabetes.</div></div><div><h3>Methods</h3><div>This prospective study included 21,129 participants with diabetes from the UK Biobank, all of whom were free of MACE and cancer at baseline. Data on habitual daytime napping and sleep duration were collected via a baseline questionnaire. Cox proportional hazards regression models were employed to assess the relationship between daytime napping and MACE, all-cause mortality, and cardiovascular disease (CVD) specific mortality. MACE was defined as a composite of myocardial infarction, heart failure, and stroke.</div></div><div><h3>Results</h3><div>Over an average 11.9-year follow-up, 5,611 MACE cases, 3,854 all-cause deaths, and 1,839 CVD deaths were identified. Compared to those who never/rarely napped, the multivariable-adjusted hazard ratios for usually napping were: 1.39 (1.08, 1.65) for MACE; 1.44 (1.01, 1.92) for myocardial infarction; 1.33 (1.07, 1.64) for heart failure; 1.57 (1.06, 2.33) for stroke; 1.28 (1.01, 1.60) for all-cause mortality; 1.33 (0.97, 1.94) for CVD mortality.</div></div><div><h3>Conclusions</h3><div>Frequent daytime napping is significantly associated with an increased risk of MACE and mortality among individuals with diabetes, particularly those who have extended sleep durations of more than 10 h and severe diabetes.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112067"},"PeriodicalIF":6.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional and national burden and trends of disease attributable to high body mass index in adolescents and young adults from 1990 to 2021","authors":"Runhong Li ,&nbsp;Jiaqi Zhang ,&nbsp;Menghan Zhang ,&nbsp;Kairui Yang ,&nbsp;Yue He ,&nbsp;Chengxiang Hu ,&nbsp;Xinli Lin ,&nbsp;Yuchun Tao ,&nbsp;Xinyao Zhang ,&nbsp;Lina Jin","doi":"10.1016/j.diabres.2025.112066","DOIUrl":"10.1016/j.diabres.2025.112066","url":null,"abstract":"<div><h3>Background</h3><div>The burden of high high body mass index (BMI) in adolescent and young adults (AYA) is largely unknown. Therefore, we aim to assess this burden.</div></div><div><h3>Methods</h3><div>Data were extracted from GBD 2021. Age-standardized mortality, DALY rates (ASMR, ASDR) and estimated annual percentage change (EAPC) were used to describe the burden. Pearson’s correlation coefficient was used to evaluate the correlation between the sociodemographic index (SDI) and ASMR/ASDR.</div></div><div><h3>Results</h3><div>From 1990 to 2021, the death and DALY number attributable to high BMI in AYA had increased by 109 % and 141 % respectively. Low-middle SDI regions showed the most significant upward trend (EAPC = 1.37 for ASMR and 1.97 for ASDR). All diseases caused by high BMI showed a upward trend except for asthma and leukemia. ASMR of this burden was negatively correlated with the SDI (r = -0.13, p &lt; 0.001), while the relationship between ASDR and SDI was opposite (r = 0.23, p &lt; 0.001). The burden of osteoarthritis caused by high BMI (r = 0.68, p &lt; 0.001), low back pain (r = 0.67, p &lt; 0.001), gout (r = 0.62, p &lt; 0.001) due to high BMI rose with SDI, which contributed to the severe DALY burden in high SDI regions.</div></div><div><h3>Conclusions</h3><div>The burden of high BMI is still rising in AYA. Targeted measures need to be taken in different regions.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112066"},"PeriodicalIF":6.1,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An evaluation of YouTube videos on glucose sensor devices and type 1 diabetes mellitus: User perceptions, device features, and content reliability","authors":"Birsel MOLU ,&nbsp;Gizem MOLU","doi":"10.1016/j.diabres.2025.112069","DOIUrl":"10.1016/j.diabres.2025.112069","url":null,"abstract":"<div><h3>Aim</h3><div>The aim of this study is to evaluate the performance, comprehensiveness, reliability, and quality of English-language YouTube videos related to new glucose sensor devices.</div></div><div><h3>Methods</h3><div>In November 2024, a search was conducted on a computer using the keywords “glucose sensor devices,” “continuous glucose monitor,” “glucose sensor devices and Type 1 Diabetes Mellitus,” and “glucose sensor devices and child.” Based on the inclusion and exclusion criteria, 30 videos that met the research objectives were analyzed. Relevant URLs were recorded. For each video, the following information was collected.</div></div><div><h3>Results</h3><div>Of the 30 videos analyzed, 40 % (n = 12) were presented or managed by healthcare professionals. The average values for performance features of the videos were: 172,257.166 ± 233,861.720 views, 170.866 ± 222.974 comments, and 1,643.133 ± 2,252.247 likes. Four videos did not receive any likes. 40 % of the videos contained good and useful information for viewers, while 60 % were of high quality.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that detailed and reliable content in YouTube videos about glucose monitoring devices enhances quality. It is recommended that video content be regularly evaluated, and future research should be conducted using alternative measurement tools in different languages.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112069"},"PeriodicalIF":6.1,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}